Research Article

Pharmacology

Pharmacology 2019;103:173–178 DOI: 10.1159/000495617 Received: October 19, 2018 Accepted after revision: November 20, 2018 Published online: January 29, 2019

Effect of Verapamil on Kidney Function Using Radionuclide Imaging

Seham Mustafa^a Abdelhamid H. Elgazzar^b Nabil Kamal^a

^aDepartment of Biomedical Sciences, College of Nursing, Public Authority for Applied Education and Training, Kuwait, Kuwait; ^bDepartment of Nuclear Medicine, Faculty of Medicine, Kuwait University, Kuwait, Kuwait

Keywords

Verapamil · Calcium channel blockers · Technetium-99m mercaptoacetyltriglycine · Renogram

Abstract

Background and Objective: Calcium channel blockers (CCBs) are among the most widely used prescribed drugs for the treatment of cardiovascular diseases. The present study investigates the effect of verapamil, which is most commonly used as a CCB, on kidney function using radionuclide imaging. Methods: Ten New Zealand white rabbits were used in vitro (4) and in vivo (6) studies. Isometric tensions were recorded for isolated renal artery ring segments, while renographic studies were performed using Technetium-99m mercaptoacetyltriglycine and Gamma camera. Time to peak activity (T_{max}) and time from peak to 50% activity ($T_{1/2}$), were calculated from the renograms for control and treated rabbits with verapamil. Results: In vitro, verapamil shifted the curve of phenylephrine concentration-dependent contraction on renal artery to the right, and decrease the highest contraction by 30 \pm 3%. In vivo, the average values of T_{max} for control and treated rabbits were 2.8 \pm 0.1 and 2.2 \pm 0.2 min respectively. The T_{1/2} for control and treated rabbits were 4.7 \pm 0.05 and 4.2 \pm 0.08 min respectively. The differences were statistically significant: p < 0.05. There is $30 \pm 4\%$ decrease in the 2 values. This indicates that there is a rapid

KARGER

© 2019 S. Karger AG, Basel

E-Mail karger@karger.com www.karger.com/pha renal uptake of the tracer and clearance of the radioactivity after verapamil. **Conclusion:** Verapamil dilates the renal artery and accelerates both the T_{max} and $T_{1/2}$ in the renogram. It increases renal blood perfusion and protects kidney function and therefore improves its work. However, verapamil should not be used while performing renograms to avoid misleading results. © 2019 S. Karger AG, Basel

Introduction

Calcium channel blockers (CCBs) are widely used in clinical practice. These drugs have been prescribed with increasing frequency because of their valuable therapeutic effects. They are used for the treatment of cardiovascular diseases such as hypertension, angina pectoris, cardiac arrhythmias, and other disorders [1–3]. All CCBs inhibit the L-type calcium channels, preventing the entry of calcium, which has a vital role in the cell. Verapamil is one of the most commonly used drug in this group [4–7]. CCBs exert also important vascular and tubular effects on the kidney [8–10]. Experimental studies in animals and humans showed the potential therapeutic uses of CCBs in decreasing the course of acute renal failure and reducing the progression of chronic renal failure. They also assist in preserving renal function in renal transplantation.

> (GER AG, BASEL 2/19/2019 3:33:58 PM

Dr. Seham Mustafa Department of Biomedical Sciences, College of Nursing Public Authority for Applied Education and Training PO BOX 23167, Safat, Kuwait (Kuwait) E-Mail mustafaseham@yahoo.com A Nuclear Medicine Renogram is performed using a specific radioactive substance; Technetium-99m (^{99m}Tc), which when injected into the blood circulation shows the kidney blood supply and filtering action of the kidneys. The radioactive substance is usually bound to other non-radioactive materials. These combined stuff is called "radionuclides", Technetium-99m mercaptoacetyltriglycine (^{99m}Tc-MAG3). The radionuclides emit energy called "photons". Once a radionuclide is distributed in the kidney, the photon energy is gathered by a "Gamma Camera". The Gamma Camera detects the pattern of distribution of the radionuclide in the urinary system and sends this information to a computer. The computer handles the information and displays the collected information in the form of a picture called renogram.

Different suitable radionuclide investigations have been used as tools to investigate physiological, pathological, and pharmacological studies for different body organs such as brain, lung, and kidney [11–21]. Renogram determines the renal function by measuring radiotracer uptake and excretion by the kidney. The images of renogram include initial cortical uptake of the radiotracer, cortical retention, first visualization of collecting system, and time to peak cortical activity and half clearance [22].

The present study investigates the effect of CCBs, verapamil, on the renal artery and on the function of the kidney using the renographic imaging technique.

Materials and Methods

Experimental Animals

Ten adult, male New Zealand white rabbits weighing 3.5–4 kg and of the same age (10 weeks) were used, 4 rabbits for in vitro experiments and 6 rabbits for in vivo imaging. The animals were handled according to the guidelines of the Institutional Animal Care and Use Committee of Kuwait University.

In vitro Experiments

Four rabbits were anesthetized with sodium pentobarbital (50-mg/kg, i.v) via the marginal ear vein. Then they were exsanguinated by cutting the carotid artery. The abdominal cavity was opened and the renal artery was isolated and placed in Krebs' solution with the following composition (in mM): NaCl 118, KCl 5.9, MgSO₄ 1.2, CaCl₂ 2.2, KH₂PO₄ 1.2, NaHCO₃ 26 and glucose 11.1, at pH 7.4. The renal arteries were cut into ring segments 4 mm in length, which were mounted on triangular wire supports and attached in 10-mL organ baths containing Krebs' solution, maintained at 37 °C and gassed continuously with 95% O₂ and 5% CO₂ mixture. Care was taken not to injure the endothelium throughout the preparation. Isometric tension of the renal artery was recorded using UF1 dynamometer transducers connected to the Multi Trace2 Lectromid recorder (Lectromid Limited, UK). The tissues were initially loaded to a tension of 1 g, which had been formerly determined as an optimal load, and al-

lowed to equilibrate for 60 min, during which time they were washed twice. Cumulative concentration curves for phenylephrine were established and then repeated after incubating the segments with verapamil (10 μ mol/L) for 30 min. The responses were calculated as % to the maximum response.

In vivo Experiments

Six adult male New-Zealand white rabbits were used for this study. All the animals were given sufficient water and food in our animal house. Butterfly needles were connected to the marginal veins in their ears. Each rabbit was anaesthetized with ketamine (40 mg/kg, i.v) given via the marginal ear vein. Furthermore, 60 mL of normal saline was given intravenously, 30 min prior to the administration of the radiopharmaceutical to confirm adequate and consistent hydration. Each rabbit served as its control and rabbits administered verapamil were referred to as treated animals.

Radionuclide Imaging

Baseline imaging studies were performed in each rabbit following injection of 48 MBq (1.3 mCi) of 99mTc-MAG3. Two days later, the same rabbit was given a single i.v dose of verapamil 2 mg and the ^{99m}Tc-MAG3 renogram repeated 20 min later. Dynamic images were acquired using Gamma camera (Meridian System, T55B-1473) equipped with a low-energy, high-resolution, parallel hole collimator interfaced with a dedicated computer. Rabbits were positioned after anesthesia in the supine position. The dynamic images were acquired in the posterior projection for 2 s frames for the first 1 min (flow phase) and every 30 s for the next 30 min (sequential functional phase) using a matrix of 64 x 64. Regions of interest were drawn over the whole kidneys manually. Radioactivity-time curves (renograms) were automatically generated and later corrected for background radioactivity for both kidneys. Curves were drawn using the Xeloris workstation (GE Medical system, version 1.06). The time to peak activity (T_{max}) , time from peak to 50% activity $(T_{1/2})$ and the uptake slope of each kidney were automatically calculated from the renograms.

Drugs

Verapamil hydrochloride and phenylephrine hydrochloride were obtained from Sigma Chemicals (St Louis, MO, USA). Verapamil hydrochloride injection (Isoptin 2.5 mg/mL ampule) from Abbott Laboratories, Ireland.

Verapamil hydrochloride was dissolved in ethanol for in vitro experiments.

Statistical Analysis

Values are presented as mean \pm (SEM) of number of rabbits (*n*) used in the studies. Differences between mean values were compared using Student *t* test paired. The difference was considered significant where *p* < 0.05.

Results

In vitro Experiments

To study the vasodilator effect of verapamil, the tone of renal artery should be elevated by a vasoconstrictor substance as phenylephrine, an α -adrenoceptor agent.



Fig. 1. Cumulative concentration-response curves of phenylephrine, PE, $(0.05-50 \mu mol/L)$ on renal artery ring segments, (**I**) before; and (**D**) with verapamil (10 μ mol/L). Each point on the graph represents mean ± SE of 4 rabbits, * p < 0.05.

Table 1. Calculated mean values of time to T_{max} and $T_{1/2}$ for the control and rabbits treated with verapamil

	^{99m} Tc-MAG3							
	T _{max}	T _{1/2}						
Control Verapamil	2.8±0.1 2.2±0.2*	4.7±0.05 4.2±0.08*						

* p < 0.05 for the comparison between control and after verapamil.

 T_{max} , time to peak activity (min); $T_{1/2}$, time from peak to 50% activity (min); 99mTc-MAG3, technetium-99m mercaptoacetylt-riglycine.

Cumulative concentration-response curves to phenylephrine were established. Phenylephrine $(0.05-50 \mu mol/L)$ produced concentration-dependent contractions of renal artery segments. The response to each concentration was allowed to reach a plateau before adding the next concentration to the bath. This was continued until the maximum response was obtained. After obtaining control responses, the tissues were washed, allowed to return to the baseline, and left to equilibrate for 60 min. Then the tissues were incubated for 30 min in the presence of CCB, verapamil 10 μ mol/L. Concentration-response curves of phenylephrine were repeated. The responses were calculated as percentage to the maximum contraction response. Verapamil shifted the curve to the right and the maximal response decreased by $30 \pm 3\%$ as shown in Figure 1.

Radionuclide Imaging

In the present study, the data collected by the gamma camera were analyzed by a computer and plotted on time graphs, renograms. Counts (how much ^{99m}Tc-MAG3 is in the kidneys) is shown on the Y axis, and time from injection is shown on the X axis. The response of each kidney is plotted separately.

Both kidneys take up the radiotracer rapidly so the curves are steeply rising between 1 and 3 min. The concentration of ^{99m}Tc-MAG3 peaks at 3–5 min and then starts to fall. The radiotracer is almost excreted and drained from the kidneys within 30 min. Renograms were normal, with time to peak of T_{max} for control and treated rabbits were 2.8 ± 0.1 and 2.2 ± 0.2 min respectively. The $T_{1/2}$ for control and treated rabbits were 4.7 ± 0.05 and 4.2 ± 0.08 min respectively. The differences were statistically significant; *p* < 0.05. After verapamil administration, the overall function increased with acceleration in cortical clearance, and the renograms were shifted to the left. There were decrease in T_{max} and $T_{1/2}$ in all treated rabbits than control and there is 30 ± 4% decrease in the 2 values as shown in Table 1.

The renograms using 99mTc-MAG3 before and after verapamil administration are shown in Figure 2a and b. After verapamil treatment, the curves shifted to the left of the control curves indicating that there was slightly increase in renal uptake of ^{99m}Tc-MAG3 and acceleration in the clearance of radioactivity. The retention of radiotracer ^{99m}Tc-MAG3 in left kidney and right kidney after 2-3 min was greater after verapamil treatment. The radiotracer did not appear in the urinary bladder within 2-3 min, while it was clearly shown after verapamil treatment, indicating fast clearance, as represented in Figure 3a and b. The sequential functional images of the same rabbit before and after verapamil administration are shown in Figure 4a and b. Evidently, acceleration in the appearance of the bladder and in the clearance of renal activity can be seen. This indicates that the blood flow to the kidney is increased by verapamil administration. Both right and left kidneys have the same results in all renograms.

Discussion

The results of this study showed that verapamil promoted renal artery vasodilatation. Therefore, induced afferent arteriolar vasodilatation, which opposes vaso-

GER AG, BASEL 2/19/2019 3:33:58 PM

Verapamil and Renogram



Fig. 2. Time activities curves (renograms) for (**a**) control rabbit; and (**b**) after verapamil treatment using ^{99m}Tc-MAG3. Note the acceleration for the peak and the clearance of activity from kidneys after verapamil.



Fig. 3. The retention of radiotracer 99m Tc-MAG3 in L Kid and R Kid after 2–3 min (**a**) control rabbit; and (**b**) after verapamil treatment. The urinary bladder did not showed radioactivity in control while there is retention of radioactivity in the bladder after verapamil treatment indicating the start of clearance. L kid, left kidney; R kid, right kidney.

NCTION IN	A065									PU	NCTION IMAGES				
•	•	•	•	•	•	•	•	•	•		••	• •	•.•	•.•	•."
•	•	•••	•	•	•	•••	•	:	•		•.*	•.*	•.'	•••	•••
	*		*		*		*		*				•••		•
	*		*		8		*		•		÷				
	1			÷	5	÷		į							

Fig. 4. Sequential functional images obtained (the dynamic images acquired for every 30 s frames for the first 30 min after administration of 99m Tc-MAG3 show more retention of radioactivity in verapamiltreated rabbit (**b**) than in control rabbit (**a**), reflecting the more clearance by the kidney.

constriction due to endogenous vasoconstrictor agents, increases vascular permeability. This will lead to an increase in the glomerular filtration rate (GFR) resulting in increased urine output. It is also known that the main effects of CBBs, as used therapeutically are on cardiac and vascular smooth muscle. They cause generalized arterial dilatation, thereby reducing blood pressure.

Their effectiveness for the treatment of essential hypertension with normal maintenance of renal function has been proven [23, 24]. In this respect, there are some reports indicating that calcium blockers are particularly effective in a subgroup of patients with essential hypertension who exhibit subtle but detectable alterations in calcium metabolism [25]. CBBs have other effects in normal animals and humans such as diuretic and natriuretic properties and inhibition of aldosterone secretion [26].

The renal artery enters the kidney and branches; one of the branches is the afferent arteriole. The afferent arteriole branches into the glomerular capillaries and the distal glomerular capillaries merge to form the efferent arteriole. Efferent arterioles subdivide to form peritubular capillaries in the cortex. The tone of the afferent and efferent glomerular arterioles can modulate glomerular capillary hydrostatic pressure. Increased tone in the afferent arteriole or decreased tone in the efferent arteriole increases the capillary hydrostatic pressure and GFR. The high hydrostatic pressure in the glomerular capillaries causes a rapid fluid filtration in the glomeruli.

Angiotensin II increases the afferent arteriolar and glomerular capillary hydrostatic pressure [27]. Angiotensin II type 1 receptors are localized in both afferent and efferent arterioles [28]. The increase in the tone of efferent arteriole decreases the hydrostatic pressure in peritubular capillaries and increases sodium and water reabsorption [29]. Renin-angiotensin system antagonists play an important role in blood pressure and renal function. The present study showed that verapamil dilates the afferent and efferent arterioles, since they need calcium to contract; therefore, it increases hydrostatic pressure in peritubular capillaries. The high hydrostatic pressure is mainly due to the difference between the afferent and efferent arterioles diameters.

Radionuclide renography plays a crucial role in assessing perfusion and kidney function. It is used for evaluating many kidney diseases and transplanted kidneys [30–34]. The cortical function is the interval between administration of the radiotracer and its excretion to the collecting system. Delayed appearance of the collecting system is related to the renal insufficiency. The interval between radiotracer administration and maximum cortical activity is another parameter of function. It can be measured from the renogram (timeactivity curve). The renogram consists of 3 phases; the first phase is the perfusion phase and renal peak activity. The second phase is the cortical or tubular concentration phase of initial parenchymal transit. This phase occurs during 1-5 min and contains the peak of the curve. The initial uptake slope closely relates with the effective renal plasma flow values. The third phase is the excretion or clearance phase that represents the down slope of the curve and is produced by excretion of the radiotracer from the kidney and clearance from the collecting system. A renogram is performed to evaluate the blood supply, function, and excretion of urine from the kidneys.

The cortical retention of ^{99m}Tc-MAG3, measured by calculating renal counts on the renogram for 20–30 min as a percentage of the peak uptake, is a measure of the quickness with which the radiotracer is excreted by the kidney. The present renogram showed almost complete excretion within 30 min for ^{99m}Tc-MAG3. Generally, as renal function improved, the percentage retained decreases.

Conclusions

Verapamil dilates the renal artery and accelerates T_{max} and $T_{1/2}$ in the renogram. It increases renal blood perfusion and GFR, protects kidney function, and improves its work. Based on the findings, it is suggested not to use CCBs when the patients have to perform renogram to avoid any misleading results of their kidney condition.

Acknowledgment

This work supported and funded by the Public Authority for Education and Training. Research Project No (CN-16-01).

We also thank Departments of Pharmacology and Nuclear Medicine, Faculty of Medicine, Kuwait University for providing the chemicals and making available the laboratory facilities to perform this research work.

Disclosure Statement

There are no possible conflicts of interest for all authors.

GER AG, BASEL :/19/2019 3:33:58 PN

References

- 1 Pai SL, Chadha RM, Irizarry-Alvarado JM, Renew JR, Aniskevich S: Pharmacologic and perioperative considerations for antihypertensive medications. Curr Clin Pharmacol 2017;12:135–140.
- 2 Prosser HC, Azzam O, Schlaich MP: Resistant hypertension: which agent? Heart Lung Circ 2018;27:911–916.
- 3 Laurent S: Antihypertensive drugs. Pharmacol Res 2017;124:116–125.
- 4 Elgendy IY, Bavry AA, Gong Y, Handberg EM, Cooper-DeHoff RM, Pepine CJ: Longterm mortality in hypertensive patients With coronary artery disease: results from the US cohort of the international verapamil (SR)/ trandolapril study. Hypertension 2016;68: 1110–1114.
- 5 Mooy J, Schols M, v Baak M, v Hooff M, Muytjens A, Rahn KH: Pharmacokinetics of verapamil in patients with renal failure. Eur J Clin Pharmacol 1985;28:405–410.
- 6 Sica D: Calcium channel blockers and the kidney. Clin Cornerstone 2004;6:39–52.
- 7 Schohn DC, Jahn HA, Maareck M: Long term effects of sustained release verapamil on the renal and systemic haemodynamic parameters in hypertensive patients with mild to severe chronic renal failure. Drugs 1993;46(suppl 2):113–119.
- 8 Segura J, García-Donaire JA, Ruilope LM: Calcium channel blockers and renal protection: insights from the latest clinical trials. J Am Soc Nephrol 2005;16(suppl 1):S64–S66.
- 9 Wenzel RR: Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005;65(suppl 2):29–39.
- 10 Chan L, Schrier RW: Effects of calcium channel blockers on renal function. Annu Rev Med 1990;41:289–302.
- 11 Mustafa S, Elgazzar AH: Effect of chronic treatment with none steroidal anti-inflammatory drug (Diclofenac) on kidney scinitgraphy. Int J Pharm Med Biol Sci 2015;4:232– 235.
- 12 Mustafa S, Alsughayer A, Elgazzar A, Elassar A, Al Sagheer F: Effect of sulfa drugs on kidney function and renal scintigraphy. Nephrology (Carlton) 2014;19:210–216.

- 13 Mustafa S, Elgazzar A: Influence of chronic exposure to cold environment on thyroid gland function in rabbits. Horm Metab Res 2014;46:546–549.
- 14 Mustafa S, Elgazzar AH: Effect of the NSAID diclofenac on 99mTc-MAG3 and 99mTc-DTPA Renography. J Nucl Med 2013;54:801– 806.
- 15 Mustafa S, Elgazzar A, Khadadah M: Lung perfusion is affected by chronic cold exposure. J Therm Biol 2013;38: 214–217.
- 16 Khadadah M, Mustafa S, Elgazzar A: Effect of acute cold exposure on lung perfusion and tracheal smooth muscle contraction in rabbit. Eur J Appl Physiol 2011;111:77–81.
- 17 Mustafa S, Al-Bader MD, Elgazzar AH, Alshammeri J, Gopinath S, Essam H: Effect of hyperthermia on the function of thyroid gland. Eur J Appl Physiol 2008;103:285–288.
- 18 Mustafa S, Elgazzar AH, Essam H, Gopinath S, Mathew M: Hyperthermia alters kidney function and renal scintigraphy. Am J Nephrol 2007;27:315–321.
- 19 Mustafa S, Elgazzar AH, Ismael HN: Influence of hyperthermia on carotid blood flow using 99mTc-HMPAO. Eur J Appl Physiol 2007;101:257–262.
- 20 Mustafa S, Thulesius O, Elgazzar AH, Ismael HN: Synergistic effects of ethanol and hyperthermia on carotid artery vasoconstriction. Clin Physiol Funct Imaging 2007;27:185–190.
- 21 Mustafa S, Elgazzar AH, Gopinath S, Mathew M, Khalil M: Effect of body temperature on the radionuclide evaluation of cerebral blood flow. World J Nucl Med 2006;5:248–252.
- 22 Esteves FP, Taylor A, Manatunga A, Folks RD, Krishnan M, Garcia EV: 99mTc-MAG3 renography: normal values for MAG3 clearance and curve parameters, excretory parameters, and residual urine volume. AJR Am J Roentgenol 2006;187:W610–W617.
- 23 Toto RD: Treatment of hypertension in chronic kidney disease. Semin Nephrol 2005; 25:435–439.

- 24 Benstein JA, Dworkin LD: Renal vascular effects of calcium channel blockers in hypertension. Am J Hypertens 1990;3(12 pt 2):305S-312S.
- 25 Romero JC, Raij L, Granger JP, Ruilope LM, Rodicio JL: Multiple effects of calcium entry blockers on renal function in hypertension. Hypertension 1987;10:140–151.
- 26 Osswald H, Weinheimer G, Kapp JF: Renal actions of calcium channel antagonists. J Neural Transm Suppl 1990;31:39–53.
- 27 Romero JC, Ruilope LM, Bentley MD, Fiksen-Olsen MJ, Lahera V, Vidal MJ: Comparison of the effects of calcium antagonists and converting enzyme inhibitors on renal function under normal and hypertensive conditions. Am J Cardiol 1988;5;62:59G-68G.
- 28 Siragy HM: AT(1) and AT(2) receptors in the kidney: role in disease and treatment. Am J Kidney Dis 2000;36(3 suppl 1):S4–S9.
- 29 Clorius JH, Schottler T, Haufe S, Zuna I, Reinbold F, van Kaick G: Afferent-efferent vessel dysfunction appears to be a specific characteristic of a large subset of patients with essential hypertension. Am J Hypertens 2000; 13(4 pt 1):332–339.
- 30 Heikkinen JO, Kuikka JT, Ahonen AK, Rautio PJ: Quality of dynamic radionuclide renal imaging: multicentre evaluation using a functional renal phantom. Nucl Med Commun 2001;22:987–995.
- 31 Turiev GS, Ametov AS, Davitinidze NL: [Radionuclide methods in the diagnosis of diabetic nephroangiopathy]. Med Radiol (Mosk) 1989;34:59–65.
- 32 Muñoz A, Puchal R, Castelao AM, Mora J, Ricart Y, Roca M, González A, Martín-Comín J: Renogram deconvolution in the management of diabetic nephropathy: utility of the measurement of initial tracer uptake. Nucl Med Commun 1997;18:1029–1035.
- 33 Paul R, Kiiliäinen H, Tarssanen L, Vorne M: [99Tcm]MAG3 gamma camera nephrography in epidemic nephritis. Nucl Med Commun 1991;12:15–25.
- 34 Eshima D, Fritzberg AR, Taylor A Jr: 99mTC renal tubular function agents: current status. Semin Nucl Med 1990;20:28–40.

Mustafa/Elgazzar/Kamal